BioSyent Inc.

TSX VENTURE : RX


BioSyent Inc.

May 23, 2014 08:00 ET

BioSyent to Present at the 2014 Marcum MicroCap Investor Conference

TORONTO, ONTARIO--(Marketwired - May 23, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the Marcum MicroCap Conference at 11am (ET), May 29, 2014 at the Grand Hyatt Hotel in New York City. Mr. Goehrum will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting the Investor Center at the www.biosyent.com website or at the following conference link http://wsw.com/webcast/marcum2/bioyf. A replay of the webcast will be available for 90 days after the presentation date. The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than $500 million in market capitalization.

Mr. Goehrum will be available for 1:1 meetings after his presentation.These meetings can be arranged via the conference organizers http://www.marcumllp.com/microcap.

To view and listen to the CEO presentation commenting on First Quarter 2014 Financial Results released May 16, 2014, please visit the following link http://www.biosyent.com/q1/.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,776,195 shares issued and outstanding.

Contact Information